Cardiovascular risk in axial spondyloarthritis: the interplay of inflammation, traditional risk factors, and management strategies
Issakulova А. Yessirkepov M. Zimba O. Kocyigit B.F.
September 2025Springer Science and Business Media Deutschland GmbH
Rheumatology International
2025#45Issue 9
Cardiovascular (CV) morbidity and mortality pose major challenges in patients with axial spondyloarthritis (AxSpA), a chronic inflammatory disorder that includes both radiographic and non-radiographic forms. Patients with AxSpA have heightened CV morbidity and mortality, mainly attributable to systemic inflammation and typical CV risk factors like hypertension, hyperlipidemia, diabetes, and obesity. Subclinical atherosclerosis frequently manifests independently of conventional risk factors and is associated with indicators of disease activity and inflammatory load. Established CV risk assessment tools generally underestimate the actual risk in AxSpA, since inflammation leads to endothelial dysfunction and promotes atherosclerosis, highlighting the necessity for customized screening strategies. Pharmacological options, including tumor necrosis factor inhibitors, have demonstrated efficacy in reducing CV risk by mitigating inflammation and improving vascular stability. The role of nonsteroidal anti-inflammatory drugs is intricate, with specific data indicating possible preventive benefits against CV events associated with favorable inflammation management. Lifestyle modifications, including smoking cessation, dietary enhancements—especially adherence to the Mediterranean diet—and increased physical activity are essential adjuncts for mitigating CV risk in this demographic. Innovative digital health technologies and integrated CV-musculoskeletal rehabilitation programs offer promising opportunities for personalized management. Despite progress, further investigation is essential to develop AxSpA-specific CV risk models, investigate sex-specific disparities, and implement multidisciplinary strategies to enhance CV outcomes. Timely identification and thorough treatments are crucial for strengthening long-term outcomes in AxSpA patients.
Ankylosing spondylitis , Axial spondyloarthritis , Cardiac rehabilitation , Cardiometabolic risk factors , Cardiovascular risk factors , Heart disease risk factors , Spondylarthritis
Text of the article Перейти на текст статьи
Department of General Practitioner N2, South Kazakhstan Medical Academy, Shymkent, Kazakhstan
Department of Chemical Disciplines, Biology and Biochemistry, South Kazakhstan Medical Academy, Shymkent, Kazakhstan
Center for Life and Health Sciences, National Academy of Sciences Under the President of the Republic of Kazakhstan, Almaty, Kazakhstan
Department of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Krakow, Poland
National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
Department of Internal Medicine N2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Department of Physical Medicine and Rehabilitation, University of Health Sciences, Adana City Research and Training Hospital, Dr. Mithat Özsan Boulevard, 4522. Street No: 28, Yüreğir, Adana, Turkey
Department of General Practitioner N2
Department of Chemical Disciplines
Center for Life and Health Sciences
Department of Rheumatology
National Institute of Geriatrics
Department of Internal Medicine N2
Department of Physical Medicine and Rehabilitation
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026